PhaseV Launches Webinar Series on AI and Data-Driven Clinical Trial Optimization
Friday, February 21, 2025
BOSTON, Feb. 13, 2025 /PRNewswire/ -- PhaseV, a pioneer in software and machine learning (ML) for advanced clinical development optimization, announced today the launch of its new webinar series exploring the latest innovations in clinical trial design and execution.
The inaugural session, Transforming Clinical Development: Leveraging AI, Real-World Evidence, and Predictive Analytics, will broadcast on Thursday, March 6 from 1:00-2:00 PM EST. Click here to register for the webinar, which will feature industry practitioners and thought leaders discussing the transformative impact of AI and data science in clinical development:
-- Etai Jacob, PhD, Senior Director, Head of Applied Data Science and AI,
Oncology R&D, AstraZeneca
-- Jacqueline Law, PhD, Vice President, Corporate Development, Flatiron
Health
-- J. Jack Lee, PhD, DDS, Professor of Biostatistics, MD Anderson Cancer
Center
Moderated by Brad Carlin PhD, Senior Director, Data Science and Statistics at PhaseV, the panel will discuss:
-- AI-driven approaches for smarter patient selection to optimize
recruitment and site selection while addressing heterogeneity in
clinical trials
-- Advances in Bayesian and adaptive trial designs that enhance flexibility
and efficiency in clinical trials
-- Leveraging real-world data for improved trial design and decision-making
-- How predictive modeling increases trial success rates and optimizes
strategic decision-making
-- Perspectives on navigating the evolving regulatory landscape for AI and
machine learning in clinical trials
The discussion will be followed by an interactive question and answer session with the panelists.
"AI and data-driven strategies are redefining clinical development," said Raviv Pryluk, PhD, CEO and Co-founder of PhaseV. "By integrating AI-powered patient selection, leveraging real-world evidence, and applying predictive modeling, we can enhance efficiency, improve decision-making, and increase trial success rates. This webinar series will bring together leading experts to share insights and real-world applications of these advancements."
About PhaseV
Leveraging the power of advanced causal inference and pushing the boundaries of ML, PhaseV detects hidden signals in clinical data and extracts actionable insights for planning the optimal next steps. The company's technology enables optimal design and closed-loop execution of adaptive clinical trials, increasing efficiency and success rates. PhaseV is advancing paradigm shifts in the clinical trial world to bring new treatments to more patients in a more precise and efficient way.
Learn more at www.phaseVtrials.com and follow us on LinkedIn.
Media Contact:
Ellie Hanson
FINN Partners for PhaseV
ellie.hanson@finnpartners.com
929-588-2008
Photo - https://mma.prnewswire.com/media/2619633/PhaseV_Webinar.jpg
Logo - https://mma.prnewswire.com/media/2267452/PhaseV_logo.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/phasev-launches-webinar-series-on-ai-and-data-driven-clinical-trial-optimization-302375833.html
SOURCE PhaseV
|
|
|
|
|
 |
Asetek - Mandatory Notification of Trade | Jan 22, 2026
|
|
Tomorrowland Brings the Magic to Shanghai for a Spectacular First Indoor Edition in China | Jan 22, 2026
|
|
BC.GAME to Host "Stay Untamed" Night During Abu Dhabi's Packed Web3 Summit Week | Jan 22, 2026
|
|
Rent Manager Earned Best Real Estate Software Product Award and Multiple Review Badges from G2 Platform | Jan 22, 2026
|
|
Auburn University's Applied Research Institute Expands Advanced Manufacturing Capabilities with CF3D Enterprise Cell | Jan 22, 2026
|
|
California Divorce Mediation Center Unveils Modern Website Redesign | Jan 22, 2026
|
|
AMPERA ANNOUNCES LOCATION FOR GLOBAL HEADQUARTERS | Jan 22, 2026
|
|
Gemmy Alerts Customers: Fake Websites Target Holiday Decorators | Jan 22, 2026
|
|
Culture and tourism sectors thrive in Xiamen | Jan 22, 2026
|
|
AMPLIFY Named Finalist in Three Categories at the 2026 Golden Gavel Awards | Jan 22, 2026
|
|
|
